New Brunswick, N.J. – Over the next ten years, Johnson & Johnson (JNJ) plans to invest a staggering $2 billion to build a state-of-the-art manufacturing facility in Holly Springs, North Carolina. By making this calculated step, the business hopes to greatly increase its production capacity in the United States and guarantee that the majority of its cutting-edge medications are made in the country for use by Americans.
About 120 new jobs are anticipated to be created in the state by the new, more than 160,000-square-foot facility that will be situated at FUJIFILM’s biopharmaceutical production plant. Over the next four years, Johnson & Johnson plans to invest $55 billion in U.S. manufacturing, R&D, and technology, which includes this project.
Read More: Johnson & Johnson Beats Q2 Estimates, Raises 2025 Outlook on Strong Sales Growth
It is anticipated that the pharmaceutical behemoth’s commitment to onshore production will improve the U.S. supply chain for vital medications. The company has already produced over 5,000 construction jobs and is currently building another facility in Wilson, North Carolina, which will employ over 500 people.
MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, […]
Johnson & Johnson’s commitment to its U.S. businesses and to guaranteeing a steady and dependable supply of medications for American patients is demonstrated by this investment. The manufacture of the company’s cutting-edge treatments will be greatly aided by the new facility, which will further establish the Research Triangle as a significant center for the life sciences sector.
Last Modified:
